BSc2118 是一种 IC50 约为 50 nM 的 20S 蛋白酶体抑制剂,可诱导骨髓瘤细胞发生 G2/M 期细胞周期阻滞和凋亡 (apoptosis),抑制细胞保护性自噬 (autophagy) 和肿瘤血管生成,降低 MMP9 活性,促进血管神经生成,并减轻重组组织型纤溶酶原激活剂诱导的脑毒性,因此可用于脑缺血和多发性骨髓瘤相关研究。
产品编号: MS-N49397 CAS No.: 863924-64-5 分子式: C28H43N3O7 分子量: 533.66
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

BSc2118 是一种 IC50 约为 50 nM 的 20S 蛋白酶体抑制剂,可诱导骨髓瘤细胞发生 G2/M 期细胞周期阻滞和凋亡 (apoptosis),抑制细胞保护性自噬 (autophagy) 和肿瘤血管生成,降低 MMP9 活性,促进血管神经生成,并减轻重组组织型纤溶酶原激活剂诱导的脑毒性,因此可用于脑缺血和多发性骨髓瘤相关研究。

生物实验数据

生物活性 BSc2118 is a 20S proteasome inhibitor with an IC50 of approximately 50 nM that induces G2/M cell cycle arrest and apoptosis in myeloma cells, inhibits cytoprotective autophagy and tumor angiogenesis, reduces MMP9 activity, promotes angiogenesis and neurogenesis, and attenuates recombinant tissue-type plasminogen activator-induced neurotoxicity, making it suitable for research related to cerebral ischemia and multiple myeloma.
IC50 & Target

MMP-9

 

体外研究
(In Vitro)

BSc2118 (0-2000 nM; 48 h) 可呈剂量依赖性地强效降低 MM.1S、MM.1R、RPMI-8226、U266 和 NCI-H929 人多发性骨髓瘤细胞系的细胞活力,在 MM.1S、MM.1R 和 RPMI-8226 细胞中的 IC50 值分别为 121.4 nM、116.8 nM 和 313.7 nM。
BSc2118 (100-200 nM; 24 h) 诱导人多发性骨髓瘤细胞系 MM.1S 发生 G2/M 期细胞周期阻滞。
BSc2118 (100-200 nM; 24 h) 诱导 MM.1S 和 MM.1R 人多发性骨髓瘤细胞呈剂量依赖性凋亡。
BSc2118 (100-200 nM; 24 h) 可上调 MM.1S 人多发性骨髓瘤细胞中 p53 和 p21 的蛋白水平。
BSc2118 (100-200 nM; 24 h) 可通过切割 caspase-9、caspase-8、caspase-3 和 PARP,在 MM.1S 和 MM.1R 人多发性骨髓瘤细胞中激活凋亡信号级联反应。
BSc2118 (100-200 nM; 3-24 h) 可强效且持续地抑制 MM.1S 人多发性骨髓瘤细胞中的 CT-L 蛋白酶体活性。
BSc2118 (100-200 nM; 3-24 h) 诱导人多发性骨髓瘤细胞 MM.1S 中泛素化蛋白的积累。
BSc2118 (200 nM; 30 h) 可抑制人脐静脉内皮细胞 (HUVECs) 的毛细血管样管形成。
BSc2118 (100-200 nM; 24 h) 可上调人脐静脉内皮细胞 (HUVECs) 中 PHD2 蛋白水平,同时下调 HIF1α 和 VE-cadherin 蛋白水平。
BSc2118 (100-200 nM; 48 h) 可呈剂量依赖性下调人 MM-BMSCs 中 IL-6、VEGFA 和 bFGF 血管生成细胞因子基因的表达。
BSc2118 (100-500 nM; 24 h) 不会诱导自噬标志物 Beclin-1 或 LC3b 的上调,反而会在Bortezomib (MS-D47138) 敏感型 ANBL-6.WT 和 Bortezomib 耐药型 ANBL-6.BR 人多发性骨髓瘤细胞中轻度降低 LC3b 水平。

Cell Cycle Analysis

Cell Line: MM.1S, MM.1R human multiple myeloma (MM) cell lines
Concentration: 100 and 200 nM
Incubation Time: 24 h
Result: Caused marked G2/M-phase arrest in MM.1S cells.
Reduced BrdU-positive cell numbers, inhibiting cell cycle progression through the G1-S transition.

Apoptosis Analysis

Cell Line: MM.1S, MM.1R human multiple myeloma (MM) cell lines
Concentration: 100 and 200 nM
Incubation Time: 24 h
Result: Induced apoptosis in a dose-dependent manner, causing a significant increase in Annexin V+ cell population.

Western Blot Analysis

Cell Line: MM.1S, MM.1R (dexamethasone-resistant) human multiple myeloma (MM) cell lines
Concentration: 100 and 200 nM
Incubation Time: 24 h
Result: Increased p53 protein levels in MM.1S cells by 1.32-fold at 100 nM and 1.81-fold at 200 nM.
Increased p21 protein levels in MM.1S cells by 1.57-fold at 100 nM and 2.20-fold at 200 nM.
Showed no increase in p53 or p21 protein levels in MM.1R cells.

Western Blot Analysis

Cell Line: MM.1S, MM.1R human multiple myeloma (MM) cell lines
Concentration: 100 and 200 nM
Incubation Time: 24 h
Result: Induced cleavage of caspase-9, caspase-8, caspase-3, and PARP in both MM.1S and MM.1R cells.
Achieved cleaved/full-length ratios in MM.1S cells of 1.23 (caspase-9, 100 nM), 1.47 (caspase-9, 200 nM), 4.67 (caspase-8, 100 nM), 12.35 (caspase-8, 200 nM), 1.18 (caspase-3, 100 nM), 5.00 (caspase-3, 200 nM), 3.25 (PARP, 100 nM), and 16.3 (PARP, 200 nM).

Western Blot Analysis

Cell Line: MM.1S human multiple myeloma (MM) cell line
Concentration: 100 and 200 nM (24 h); 100 nM (3, 12 and 24 h)
Incubation Time: 3, 12 and 24 h
Result: Increased ubiquitinated protein levels in MM.1S cells by 1.25-fold at 100 nM for 24 h, 1.38-fold at 200 nM for 24 h, 1.14-fold at 100 nM for 3 h, 1.14-fold at 100 nM for 12 h, and 1.23-fold at 100 nM for 24 h relative to control.

Western Blot Analysis

Cell Line: Human umbilical vein endothelial cells (HUVECs)
Concentration: 100 and 200 nM
Incubation Time: 24 h; 4 h (TNFα/CoCl2 co-treatment)
Result: Increased PHD2 protein levels in HUVECs by 2.95-fold at 100 nM and 1.88-fold at 200 nM under normoxia, 2.11-fold at 100 nM and 1.02-fold at 200 nM with TNFα, and 1.56-fold at 100 nM and 1.35-fold at 200 nM with CoCl2.
Decreased HIF1α expression to 0.90-fold at 100 nM and 0.78-fold at 200 nM under normoxia, 0.79-fold at 100 nM and 0.66-fold at 200 nM with TNFα, and 0.95-fold at 100 nM and 0.89-fold at 200 nM with CoCl2.
Decreased VE-cadherin expression to 0.69-fold at 100 nM and 0.43-fold at 200 nM under normoxia, 0.41-fold at 100 nM and 0.23-fold at 200 nM with TNFα, and 0.29-fold at 100 nM and 0.36-fold at 200 nM with CoCl2.

Real Time qPCR

Cell Line: Human MM bone marrow stromal cells (MM-BMSCs)
Concentration: 100 and 200 nM
Incubation Time: 48 h
Result: Reduced IL-6 gene expression to ~0.7-fold at 100 nM and ~0.2-fold at 200 nM relative to control.
Reduced VEGFA gene expression to ~0.8-fold at 100 nM and ~0.5-fold at 200 nM relative to control.
Reduced bFGF gene expression to ~1.6-fold at 100 nM and ~0.9-fold at 200 nM relative to control.
Inhibited gene expression in a dose-dependent manner.

Western Blot Analysis

Cell Line: ANBL-6.WT (bortezomib-sensitive), ANBL-6.BR (bortezomib-resistant) human multiple myeloma (MM) cell lines
Concentration: 100 and 200 nM (ANBL-6.WT); 500 nM (ANBL-6.BR)
Incubation Time: 24 h
Result: Reduced Beclin-1 levels in ANBL-6.WT cells to 0.97-fold at 100 nM and 0.68-fold at 200 nM relative to control.
Reduced LC3b levels in ANBL-6.WT cells to 0.79-fold at 100 nM and 0.82-fold at 200 nM relative to control.
Reduced Beclin-1 levels in ANBL-6.BR cells to 0.82-fold at 500 nM relative to control.
Reduced LC3b levels in ANBL-6.BR cells to 0.37-fold at 500 nM relative to control.
Failed to up-regulate Beclin-1 or LC3b in either cell line.
体内研究
(In Vivo)

BSc2118 (10-60 mg/kg;纹状体内注射;单剂量) 可对雄性 C57BL/6N 小鼠的再灌注诱导性脑缺血产生急性及长期神经保护作用,并改善长期神经元存活、功能恢复、血管神经发生及血脑屏障稳定性。
BSc2118 (30 mg/kg;腹腔注射;每周 2 次;持续 3 周) 可在多发性骨髓瘤 NOD/SCID 小鼠模型中使肿瘤体积缩小 61.5%,抑制肿瘤血管生成并降低基础自噬水平,且未观察到血液学毒性。

Animal Model: C57BL/6N (adult male, reperfusion-induced cerebral ischaemia model)
Dosage: 10 mg/kg (12h pre-stroke); 30 mg/kg (12h pre-stroke, 6h post-stroke, 12h post-stroke); 60 mg/kg (12h pre-stroke)
Administration: intrastriatal injection; single dose
Result: Induced long-term neuroprotection (lasting up to 3 months), significantly reduce the volume of cerebral infarction, and improve motor coordination and cognitive deficits.
Inhibited the proteasomal degradation of the transcription factor hypoxia-inducible factor 1α (HIF1A), resulting in a significant accumulation of its protein level.
Enhanced post-ischemic angiogenesis and neurogenesis, accompanied by an increase in the levels of pro-angiogenic and neurotrophic factors (such as erythropoietin, brain-derived neurotrophic factor, and vascular endothelial growth factor).
Reduced the secondary brain injury, bleeding and disruption of the blood-brain barrier caused by the thrombolytic drug recombinant tissue-type plasminogen activator (rt-PA).
Animal Model: NOD/SCID mice
Dosage: 30 mg/kg
Administration: i.p.; twice a week; 3 weeks
Result: Reduced tumor volume by 61.5% compared to vehicle control.
Reduced density of CD31-positive blood vessels (microvessel density) in tumor tissues.
Decreased number of endothelial cells and surrounding pericytes.
Diminished basal levels of autophagy markers Beclin-1 and LC3b in tumor tissues.
Showed no hematologic toxicity (unchanged serum hemoglobin, white blood cell counts, and platelet counts) relative to the control group.

化学信息

分子量 533.66
分子式 C28H43N3O7
CAS No. 863924-64-5

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础